Holen Sie sich die Stockscreener-App
400.71
2.54%
9.92
Schlusskurs vom Vortag:
$390.79
Offen:
$392.9
24-Stunden-Volumen:
1.01M
Relative Volume:
0.50
Marktkapitalisierung:
$57.76B
Einnahmen:
$2.50B
Nettoeinkommen (Verlust:
$-226.32M
KGV:
-244.16
EPS:
-1.6412
Netto-Cashflow:
$71.51M
1W Leistung:
-5.86%
1M Leistung:
+21.82%
6M Leistung:
+107.59%
1J Leistung:
+136.73%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$380.39
$437.41
52-Wochen-Spanne:
$167.99
$437.41
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
400.71 | 57.76B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
658.02 | 243.30B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
219.81 | 154.52B | 24.78B | 3.68B | 5.29B | 5.1743 |
A
Agilent Technologies Inc
|
170.54 | 48.08B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
259.88 | 42.78B | 16.63B | 1.39B | 2.12B | 8.0674 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-09 | Fortgesetzt | UBS | Buy |
| 2026-09-08 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2026-06-26 | Fortgesetzt | Bernstein | Outperform |
| 2026-06-12 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2026-06-02 | Fortgesetzt | Wolfe Research | Outperform |
| 2026-04-14 | Eingeleitet | William Blair | Outperform |
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Matthew Rabinowitz Donates 6,000 Natera Shares to Charity on October 7, 2026 - Kalkine Media
Natera CEO Steven Chapman sells $526k in common stock - Investing.com
Natera (NTRA) clinical diagnostics president sells 3,000 shares under a trading plan. - Stock Titan
Morgan Stanley Smith Barney is broker for a proposed 1,273-share sale at Natera (NTRA). - Stock Titan
After five sales in three months, a Natera (NTRA) officer proposes another stock sale. - Stock Titan
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Australia
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Nigeria
Under a preset plan, two trusts sold 18,064 Natera (NTRA) shares in 12 transactions. - Stock Titan
Natera Director Sheena Jonathan to Offload 21,064 Shares Worth $8.16M, Form 144 Filed - Kalkine Media
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx - Zacks Investment Research
$8.2M stock sale planned at Natera (NASDAQ: NTRA) - Stock Titan
Natera (NASDAQ: NTRA) co-founder sells 9,150 shares under 10b5-1 plan - Stock Titan
Natera (NASDAQ: NTRA) chair unloads stock in preset plan - Stock Titan
Trust tied to Natera (NASDAQ: NTRA) eyes new stock sale after multimillion-dollar trades - Stock Titan
Understanding Momentum Shifts in (NTRA) - Stock Traders Daily
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - webull.com
Natera(NTRA.US) Officer Sells US$16.4 Million in Common Stock - Moomoo
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com South Africa
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - Investing.com
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com India
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - investing.com
Executive chair of Natera (NTRA) sells 50,000 shares - Stock Titan
Insider at Natera (NTRA) plans stock sale, with size detailed in new SEC notice - Stock Titan
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - simplywall.st
NTRA Maintains Buy Rating by UBS -- Price Target Raised to $435 - GuruFocus
3 Reasons Investors Love Natera (NTRA) - Yahoo Finance
UBS Adjusts Price Target on Natera to $435 From $290, Keeps Buy Rating - Moomoo
Jim Cramer Calls Natera (NTRA) “a Promising Story” - Yahoo Finance
Net current asset value per share of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA - TradingView
3 Reasons Investors Love Natera (NTRA) - TradingView
Fed. Circ. Urged To Overturn Natera's Cancer Test Patent Win - Law360
Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia) - The Motley Fool
NTRA Initiated Coverage by Rothschild & Co -- Price Target Set a - GuruFocus
Can Natera (NTRA) Justify Its Valuation As Signatera Lymphoma Data Lifts Sentiment? - simplywall.st
Can Natera (NTRA) Justify Its Valuation As Signatera Lymphoma Data Lifts Sentiment? - simplywall.st
Rothschild Redburn initiates Natera stock with buy on MRD leadership By Investing.com - Investing.com Nigeria
Rothschild Redburn initiates Natera stock with buy on MRD leadership By Investing.com - Investing.com Canada
Rothschild Redburn initiates Natera stock with buy on MRD leadership - Investing.com
Rothschild Redburn initiates Natera stock with buy on MRD leadership - Investing.com
Debt to assets ratio of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAD - TradingView
Net debt of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - tradingview.com
Natera, Inc. (NTRA) Stock Analysis: A $47.31 Billion Healthcare Innovator with Strong Buy Ratings - DirectorsTalk Interviews
Net income before discontinued operations of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAD - TradingView
Price to earnings forward of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - tradingview.com
Diluted earnings per share (diluted EPS) of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - TradingView
Gross profit of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA - TradingView
Natera Inc Cert Deposito Arg Repr 0.019607 Sh Revenue Breakdown – BCBA:NTRA.CI - TradingView
Natera Inc Cert Deposito Arg Repr 0.019607 Sh Revenue Breakdown – BCBA:NTRA - TradingView
Natera, Inc.Common Stock (NQ: NTRA - FinancialContent
Guggenheim maintains Buy on Natera, raises target to $290 - scanx.trade
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Natera Inc-Aktie (NTRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Oct 01 '26 |
Sale |
414.22 |
3,000 |
1,242,645 |
106,914 |
| SOLOMON MOSHKEVICH | Officer |
Oct 01 '26 |
Proposed Sale |
414.22 |
3,000 |
1,242,645 |
0 |
| STEVEN L CHAPMAN | Officer |
Oct 01 '26 |
Proposed Sale |
413.31 |
1,273 |
526,144 |
0 |
| Sheena Jonathan | Director |
Sep 23 '26 |
Proposed Sale |
387.55 |
21,064 |
8,163,402 |
0 |
| Sheena Jonathan | CO-FOUNDER |
Sep 23 '26 |
Sale |
388.01 |
18,064 |
7,008,972 |
9,000 |
| Sheena Jonathan | CO-FOUNDER |
Sep 16 '26 |
Sale |
354.19 |
3,150 |
1,115,714 |
221,314 |
| TINKERBELLE II TR U/A DTD 10/2 | Officer |
Sep 15 '26 |
Proposed Sale |
350.01 |
2,000 |
700,015 |
0 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Sep 15 '26 |
Sale |
350.01 |
2,000 |
700,014 |
0 |
| Sheena Jonathan | CO-FOUNDER |
Sep 15 '26 |
Sale |
350.07 |
6,000 |
2,100,431 |
224,464 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Sep 15 '26 |
Sale |
347.19 |
50,000 |
17,359,280 |
2,125,394 |
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):